AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance

U.S. Markets open in 53 mins.

AstraZeneca PLC (AZN.L)


LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,653.00-33.50 (-0.71%)
As of 1:22PM BST. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close4,686.50
Open4,679.50
Bid4,653.00 x 6100
Ask4,653.50 x 13000
Day's Range4,604.00 - 4,775.56
52 Week Range3,680.00 - 5,505.00
Volume683,986
Avg. Volume2,502,839
Market Cap58.89B
Beta0.61
PE Ratio (TTM)16.86
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.80 (4.81%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters2 hours ago

    AstraZeneca aims to escape drug sales trough in second half

    AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Chief Executive Pascal Soriot believes 2017 will mark the trough for the British group, as it starts to put generic losses behind it and builds up sales of recently launched and experimental cancer medicines. Industry analysts, on average, had forecast revenue of $5.4 billion and earnings of 82 cents, according to Thomson Reuters data.

  • The Wall Street Journal2 hours ago

    [$$] AstraZeneca Profit Drops on Decline in Blockbuster-Drug Revenue

    U.K. drug maker AstraZeneca, battling declining sales of its blockbuster cholesterol pill, posted lower revenue and profit in the first quarter of the year.

  • AstraZeneca Core Earnings Rise Despite Sales Slide; Key I-O Trial Eyed
    Investor's Business Daily3 hours ago

    AstraZeneca Core Earnings Rise Despite Sales Slide; Key I-O Trial Eyed

    The U.K. drug giant reported higher adjusted EPS even as sales continued to fall. AstraZeneca is pinning its hopes on a key immunotherapy drug trial.